|
gptkbp:instanceOf
|
gptkb:drug
gptkb:proton_pump_inhibitor
|
|
gptkbp:approvalYear
|
2000
|
|
gptkbp:ATCCode
|
A02BC05
|
|
gptkbp:bioavailability
|
50-90%
|
|
gptkbp:brand
|
gptkb:Nexium
|
|
gptkbp:CASNumber
|
119141-88-7
|
|
gptkbp:category
|
gptkb:benzimidazole
gptkb:drug
gptkb:World_Health_Organization_essential_medicines
gptkb:proton_pump_inhibitor
sulfoxide
AstraZeneca brand
chiral drug
gastroenterology drug
|
|
gptkbp:contraindication
|
hypersensitivity to esomeprazole
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:drugClass
|
gptkb:proton_pump_inhibitor
|
|
gptkbp:eliminationHalfLife
|
1-1.5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasEnantiomer
|
gptkb:omeprazole
|
|
gptkbp:hasMolecularFormula
|
C17H19N3O3S
|
|
gptkbp:interactsWith
|
gptkb:phenytoin
gptkb:warfarin
gptkb:clopidogrel
gptkb:methotrexate
gptkb:diazepam
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits H+/K+ ATPase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B3 (Australia)
Category C (US)
|
|
gptkbp:proteinBinding
|
97%
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
abdominal pain
constipation
headache
|
|
gptkbp:synonym
|
gptkb:Nexium
S-omeprazole
|
|
gptkbp:usedFor
|
gptkb:Zollinger-Ellison_syndrome
gptkb:gastroesophageal_reflux_disease
gptkb:peptic_ulcer_disease
|
|
gptkbp:bfsParent
|
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Esomeprazole
|